Related Experiment Video
Updated: Jul 2, 2025
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Decrease in Mycophenolate Mofetil Plasma Concentration in the Presence of Antibiotics: A Case Report in a Cystic
Giuliano Ponis1, Giuliana Decorti2, Egidio Barbi1,2
1Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", 34137 Trieste, Italy.
Abstract:
Immunosuppression management in transplant recipients is a critical component of pharmacotherapy. This becomes particularly crucial when patients are exposed to multiple medications that may lead to pharmacological interactions, potentially compromising the effectiveness of immunosuppression. We present the case of a 46-year-old patient diagnosed with cystic fibrosis in childhood at our hospital, who underwent bilateral lung transplantation and is undergoing immunosuppressive therapy. The patient was hospitalized due to an acute pulmonary exacerbation. During the hospitalization, the patient was administered various classes of antibiotics while continuing the standard antirejection regimen of everolimus and mycophenolate. Plasma concentrations of immunosuppressants, measured after antibiotic therapy, revealed significantly lower levels than the therapeutic thresholds, providing the basis for formulating the hypothesis of a drug-drug interaction phenomenon. This hypothesis is supported by the rationale of antibiotic-induced disruption of the intestinal flora, which directly affects the kinetics of mycophenolate. These levels increased after discontinuation of the antimicrobials. Patients with CF undergoing lung transplantation, especially prone to pulmonary infections due to their medical condition, considering the enterohepatic circulation of mycophenolate mediated by intestinal bacteria, necessitate routine monitoring of mycophenolate concentrations during and immediately following the cessation of antibiotic therapies, that could potentially result in insufficient immunosuppression.
Insights
Antibiotics can lower immunosuppressant levels in lung transplant patients with cystic fibrosis by disrupting gut bacteria. Monitoring mycophenolate levels during and after antibiotic treatment is vital to prevent organ rejection.
Area of Science:
- Pharmacology
- Transplantation Medicine
- Microbiology
Background:
- Effective immunosuppression is crucial for transplant recipients, particularly those on multiple medications.
- Drug interactions can compromise immunosuppressive therapy efficacy.
- Cystic fibrosis patients undergoing lung transplantation are prone to infections requiring antibiotic treatment.
Observation:
- A 46-year-old lung transplant recipient with cystic fibrosis experienced reduced immunosuppressant levels (everolimus and mycophenolate) during antibiotic therapy for a pulmonary exacerbation.
- These immunosuppressant levels normalized after antibiotic discontinuation.
Findings:
- A drug-drug interaction between antibiotics and immunosuppressants was hypothesized.
- Antibiotic-induced disruption of intestinal flora likely affected the enterohepatic circulation and pharmacokinetics of mycophenolate.
- Reduced mycophenolate levels fell below therapeutic thresholds during antibiotic treatment.
Implications:
- Lung transplant recipients with cystic fibrosis require vigilant monitoring of mycophenolate concentrations during and after antibiotic courses.
- This monitoring is essential to prevent sub-therapeutic immunosuppression and potential graft rejection.
- Understanding the impact of gut microbiota on drug metabolism is critical in managing complex transplant patients.
Related Concept Videos
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...